Alivia Kaylor

Danvers

Senior Editor at Pharma News Intelligence

Senior Editor at PharmaLifeScience

Featured in: Favicon

pharmanewsintel.com Favicon

healthitanalytics.com Favicon

techtarget.com

Articles

Novo Nordisk ends Hims & Hers partnership over GLP-1 safety concerns

4 days ago | techtarget.com | Alivia Kaylor

Ca-ssis/istock via Getty Images Wegovy maker ended its month-old telehealth partnership with Hims & Hers over alleged deceptive marketing of compounded GLP-1 drugs from overseas suppliers, citing safety risks.
Extensive patent strategies drive U.S. drug price disparities

4 days ago | techtarget.com | Alivia Kaylor

Patent extensions for drugs like apixaban (Eliquis) and semaglutide could add $200B+ to U.S. costs and delay access to affordable alternatives, despite Medicare price negotiations.
Oracle unveils offline EHR for remote care settings

1 week ago | techtarget.com | Alivia Kaylor

elenabs/istock via getty images Oracle Health Community Care offers offline EHR access to support remote and in-home care delivery in areas with limited broadband or unreliable internet connectivity.
FDA voucher program expedites high-need drug approvals

1 week ago | techtarget.com | Alivia Kaylor

elenabs/istock via Getty Images The FDA's new voucher program fast-tracks drug reviews to 1–2 months for therapies that address U.S. health crises, unmet needs or national security priorities.
GLP-1 real-world weight loss falls short of trial results

1 week ago | techtarget.com | Alivia Kaylor

elenabs/istock via getty images GLP-1 drugs like semaglutide and tirzepatide deliver lower weight loss in real-world use than in clinical trials, due to early discontinuation, suboptimal dosing and access challenges.
RFK Jr. names 8 new members to CDC vaccine advisory committee

2 weeks ago | techtarget.com | Alivia Kaylor

filo/DigitalVision Vectors via G RFK Jr. appoints eight new members to the CDC Advisory Committee on Immunization Practices, days after firing the panel's 17 sitting members.
How oral GLP-1 drugs could disrupt the weight loss market

2 weeks ago | techtarget.com | Alivia Kaylor

Ca-ssis/istock via Getty Images FDA-approved oral GLP-1 formulations for weight loss could disrupt the weight management market, outcompete injectables and reduce patient access barriers.
RFK Jr. removes all 17 members of vaccine advisory committee

2 weeks ago | techtarget.com | Alivia Kaylor

HHS Secretary RFK Jr. removes all 17 CDC vaccine advisory panel members, sparking industry concerns over vaccine policy, patient access and public trust.
FDA launches gen AI Elsa to support clinical, regulatory tasks

3 weeks ago | techtarget.com | Alivia Kaylor

The FDA is scaling up the rollout of Elsa, an in-house generative AI tool designed to assist with clinical protocol reviews, adverse event summaries and internal data tasks.
FDA ends GLP-1 compounding for semaglutide, tirzepatide

3 weeks ago | techtarget.com | Alivia Kaylor

By Alivia Kaylor, MSc, Senior Editor Published: 02 Jun 2025 The FDA has officially removed semaglutide and tirzepatide -- the active pharmaceutical ingredients behind blockbuster GLP-1 receptor agonists like Wegovy, Ozempic, Mounjaro and Zepbound -- from the national drug shortage list.